FINWIRES · TerminalLIVE
FINWIRES

SKB Biopharma's New Indication Application for Breast Cancer Drug Candidate Accepted in China

By

Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990, SHE:002422) new indication application for TROP2 ADC sacituzumab tirumotecan was accepted for review by China's National Medical Products Administration.

The drug has been developed for the first-line treatment of patients with recurrent or metastatic triple-negative breast cancer, according to a Thursday Hong Kong bourse filing.

This is the sixth indication application accepted by the regulator for the product. The acceptance was based on positive results from a phase III registrational study.

Related Articles